Enlivex to Present 3-Month Topline Data from Phase IIa Moderate/Severe Knee Osteoarthritis Trial on August 18 Webinar

Rhea-AI Summary

Enlivex Therapeutics (Nasdaq: ENLV) announced a webinar scheduled for August 18, 2025, at 8:00 AM ET to present 3-month topline results from its Phase IIa trial of Allocetra™ for moderate to severe knee osteoarthritis. The study, ENX-CL-05-001, is a double-blind, randomized, placebo-controlled multi-center trial.

The trial has enrolled 134 patients who have completed the 3-month follow-up period. The Phase IIa stage follows a completed Phase I open-label dose-escalation study that evaluated safety, tolerability, and optimal dosing. The trial addresses knee osteoarthritis, which affects over 32.5 million Americans and 300 million people worldwide, with 40% of men and 47% of women developing it in their lifetimes.

News Market Reaction

+14.10% 2.1x vol

21 alerts

+14.10% News Effect

+29.7% Peak in 22 hr 23 min

+$5M Valuation Impact

$44M Market Cap

2.1x Rel. Volume

On the day this news was published, ENLV gained 14.10%, reflecting a significant positive market reaction. Argus tracked a peak move of +29.7% during that session. Our momentum scanner triggered 21 alerts that day, indicating elevated trading interest and price volatility. This price movement added approximately $5M to the company's valuation, bringing the market cap to $44M at that time. Trading volume was elevated at 2.1x the daily average, suggesting notable buying interest.

Data tracked by StockTitan Argus on the day of publication.

Webinar to Review Results from Multi-Center, Randomized, Double-Blind, Placebo-Controlled Study Evaluating Allocetra™ in Patients with Moderate to Severe Knee Osteoarthritis

Nes-Ziona, Israel, Aug. 14, 2025 (GLOBE NEWSWIRE) -- Enlivex Therapeutics Ltd. (Nasdaq: ENLV, the “Company”), a clinical-stage macrophage reprogramming immunotherapy company, today announced it will host a webinar on Monday, August 18, 2025, at 8:00 AM Eastern Time to present and discuss 3-month topline results from the Phase IIa stage of its Phase I/IIa ENX-CL-05-001 trial, a double-blind, randomized, placebo-controlled multi-centered study.
  
The webinar will feature a detailed analysis of 3-month topline data from the Phase IIa stage of ENX-CL-05-001, a multi-center, two-stage Phase I/II trial evaluating Allocetra™ in patients with moderate-to-severe knee osteoarthritis.

Register now to reserve your spot for the webinar: https://www.redchip.com/webinar/ENLV/87053863717

Osteoarthritis, the most common form of arthritis, affects more than 32.5 million Americans and more than 300 million people worldwide; symptomatic knee osteoarthritis is especially prevalent and disabling, with 40% of men and 47% of women developing it in their lifetimes. The first stage of the trial, a Phase I open-label dose-escalation study, was completed to evaluate safety and tolerability and to determine optimal dosing.

The ongoing Phase IIa stage is a double-blind, randomized, placebo-controlled trial, assessing both safety and efficacy, with endpoints measuring joint pain and function versus placebo at 3, 6, and 12 months post-injection. An interim analysis, conducted by an independent third party, was designed to evaluate the potential benefits of expanding enrollment from 130 to 180 patients and to identify possible responder sub-populations. To date, 134 patients have completed the 3-month follow-up period, the trial’s primary timepoint for measuring key endpoints.

ABOUT ENLIVEX

Enlivex is a clinical stage macrophage reprogramming immunotherapy company developing Allocetra™, a universal, off-the-shelf cell therapy designed to reprogram macrophages into their homeostatic state. Resetting non-homeostatic macrophages into their homeostatic state is critical for immune system rebalancing and resolution of life-threatening and life debilitating conditions. For more information, visit https://enlivex.com/.

Safe Harbor Statement: This press release contains forward-looking statements, which may be identified by words such as “expects,” “plans,” “projects,” “will,” “may,” “anticipates,” “believes,” “should,” “would,” “could,” “intends,” “estimates,” “suggests,” “target,” “has the potential to” and other words of similar meaning, including statements regarding expected cash balances, expected clinical trial results, market opportunities for the results of current clinical studies and preclinical experiments, the effectiveness of, and market opportunities for, ALLOCETRA^TM programs. All such forward-looking statements are made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. Investors are cautioned that forward-looking statements involve risks and uncertainties that may affect Enlivex’s business and prospects, including the risks that Enlivex may not succeed in generating any revenues or developing any commercial products; that the products in development may fail, may not achieve the expected results or effectiveness and/or may not generate data that would support the approval or marketing of these products for the indications being studied or for other indications; that ongoing studies may not continue to show substantial or any activity; and other risks and uncertainties that may cause results to differ materially from those set forth in the forward-looking statements. The results of clinical trials in humans may produce results that differ significantly from the results of clinical and other trials in animals. The results of early-stage trials may differ significantly from the results of more developed, later-stage trials. The development of any products using the ALLOCETRA^TM product line could also be affected by a number of other factors, including unexpected safety, efficacy or manufacturing issues, additional time requirements for data analyses and decision making, the impact of pharmaceutical industry regulation, the impact of competitive products and pricing and the impact of patents and other proprietary rights held by competitors and other third parties. In addition to the risk factors described above, investors should consider the economic, competitive, governmental, technological and other factors discussed in Enlivex’s filings with the Securities and Exchange Commission, including in the Company’s most recent Annual Report on Form 20-F filed with the Securities and Exchange Commission. The forward-looking statements contained in this press release speak only as of the date the statements were made, and we do not undertake any obligation to update forward-looking statements, except as required under applicable law.

ENLIVEX CONTACT

Shachar Shlosberger, CFO
Enlivex Therapeutics, Ltd.
shachar@enlivexpharm.com

INVESTOR RELATIONS CONTACT

Dave Gentry, CEO
RedChip Companies Inc.
1-407-644-4256
ENLV@redchip.com

FAQ

When will Enlivex (ENLV) present its Phase IIa knee osteoarthritis trial results?

Enlivex will present the 3-month topline results during a webinar on August 18, 2025, at 8:00 AM Eastern Time.

How many patients completed the 3-month follow-up in Enlivex's Phase IIa osteoarthritis trial?

134 patients have completed the 3-month follow-up period, which is the trial's primary timepoint for measuring key endpoints.

What is the design of Enlivex's ENX-CL-05-001 osteoarthritis trial?

The trial is a double-blind, randomized, placebo-controlled multi-center study evaluating Allocetra™ in patients with moderate to severe knee osteoarthritis.

What is the potential patient population for Enlivex's knee osteoarthritis treatment?

The treatment addresses a significant market, with over 32.5 million Americans and 300 million people worldwide affected by osteoarthritis, including 40% of men and 47% of women developing knee osteoarthritis in their lifetimes.

What are the endpoints being measured in Enlivex's Phase IIa osteoarthritis trial?

The trial is measuring joint pain and function versus placebo at 3, 6, and 12 months post-injection.